Phase II Study of Osimertinib in Patients With Epidermal Growth Factor Receptor Mutations: Results From the NCI-MATCH ECOG-ACRIN (EAY131) Trial Subprotocol E.
Chen MF, Song Z, Yu HA, Sequist LV, Lovly CM, Mitchell EP, Moscow JA, Gray RJ, Wang V, McShane LM, Rubinstein LV, Patton DR, Williams PM, Hamilton SR, Umemura Y, Tricoli JV, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT.
Chen MF, et al. Among authors: flaherty kt.
JCO Precis Oncol. 2024 Apr;8:e2300454. doi: 10.1200/PO.23.00454.
JCO Precis Oncol. 2024.
PMID: 38591867
Clinical Trial.